Plasma branched-chain amino acid concentrations in individuals without cardiovascular diseases versus patients diagnosed with hypertension and coronary artery disease

Aim. Branched-chain amino acids (BCAAs) have been postulated as potential indicators of cardiovascular risk. The objective of this study was to explore the relationship between plasma BCAAs and different stages of cardiovascular disorders.

Material and methods. In our cross-sectional study, plasma BCAAs (valine, leucine and isoleucine) in individuals without cardiovascular diseases (CVDs) (nonCVD group, total n=27, with n=16 healthy, but with metabolic disorders) were compared to patients diagnosed with CVDs [CVD group, total n=109, being n=61 hypertension (n=31 with signs of beginning of myocardial remodeling) and n=48 patients with coronary artery disease (CAD)].

Results. The plasma concentration of BCAAs was significantly higher in the group of patients with cardiovascular disease compared with the healthy group (p<0.05 for all amino acids tested): valine concentration was 238.7 [219.6; 267.0] μM in the non-CVD group and 261.2 [233.8; 298.7] μM in the CVD group; leucine concentration was 134.8 [122.4; 153.2] μM and 146.8 [129.0; 166.6] μM, respectively; and isoleucine 72.7 [65.3; 84.4] μM and 81.7 [68.0; 96.2] μM, respectively. Leucine and isoleucine concentration levels were minimal in the healthy participant subgroup and maximal in the IBS patient subgroup. No statistically significant differences in BCAAs concentrations were found in the subgroups without CAD. Significant increases in concentrations were observed in the subgroups of patients with CAD as follows: valine concentration was 256.3 [219.0; 297.9] μM in hypertension group and 261.7 [236.5; 307.5] μM in CAD group; leucine concentration was 141.8 [123.5; 166.6] μM and 154.1 [134.7; 172.7] μM, respectively, and isoleucine 72.8 [65.7; 94.0] μM and 85.7 [74.9; 101.7] μM, respectively. BCAAs profiles in all participants with metabolic disorders had “good” diagnostic accuracy with area under the receiver operating characteristics curve being 0.72, 0.70 and 0.70 for valine, leucine and isoleucine, respectively.

Conclusion. BCAAs concentrations are elevated with higher severity of the cardiovascular disorder and exhibit potential as early independent indicators of coronary artery disease.

1. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121(4 Pt 1):1244-63. DOI:10.1016/0002-8703(91)90694-d.

2. Taegtmeyer H, Young ME, Lopaschuk GD, et al. American Heart Association Council on Basic Cardiovascular Sciences. Assessing Cardiac Metabolism: A Scientific Statement From the American Heart Association. Circ Res. 2016;118(10):1659-701. DOI:10.1161/RES.0000000000000097.

3. Kukharenko A, Brito A, Kozhevnikova MV, et al. Relationship between the plasma acylcarnitine profile and cardiometabolic risk factors in adults diagnosed with cardiovascular diseases. Clin Chim Acta. 2020;507:250-256. DOI:10.1016/j.cca.2020.04.035.

4. Nie C, He T, Zhang W, Ma X. Branched Chain Amino Acids: Beyond Nutrition Metabolism. Int J Mol Sci. 2018;19(4):954. DOI:10.3390/ijms19040954.

5. Li T, Zhang Z, Kolwicz SC Jr, et al. Defective Branched-Chain Amino Acid Catabolism Disrupts Glucose Metabolism and Sensitizes the Heart to Ischemia-Reperfusion Injury. Cell Metab. 2017;25(2):374-385. DOI:10.1016/j.cmet.2016.11.005.

6. Wagenmakers AJ, Veerkamp JH. Degradation of branched-chain amino acids and their derived 2-oxo acids and fatty acids in human and rat heart and skeletal muscle. Biochem Med. 1982;28(1):16-31. DOI:10.1016/00062944(82)90051-5.

7. Herman MA, She P, Peroni OD, et al. Adipose tissue branched chain amino acid (BCAA) metabolism modulates circulating BCAA levels. J Biol Chem. 2010;285(15):11348-56. DOI:10.1074/jbc.M109.075184.

8. Zhang L, Wei TT, Li Y, et al. Functional Metabolomics Characterizes a Key Role for N-Acetylneuraminic Acid in Coronary Artery Diseases. Circulation. 2018;137(13):1374-1390. DOI:10.1161/CIRCULATIONAHA.117.031139.

9. Yang R, Dong J, Zhao H, et al. Association of branched-chain amino acids with carotid intima-media thickness and coronary artery disease risk factors. PLoS One. 2014;9(6):e99598. DOI:10.1371/journal.pone.0099598.

10. Yang P, Hu W, Fu Z, et al. The positive association of branched-chain amino acids and metabolic dyslipidemia in Chinese Han population. Lipids Health Dis. 2016;15:120. DOI:10.1186/s12944-016-0291-7.

11. Mels CM, Schutte AE, Schutte R, et al. The link between vascular deterioration and branched chain amino acids in a population with high glycated haemoglobin: the SABPA study. Amino Acids. 2013;45(6):1405-13. DOI:10.1007/s00726-013-1611-0.

12. Magnusson M, Lewis GD, Ericson U, et al. A diabetes-predictive amino acid score and future cardiovascular disease. Eur Heart J. 2013;34(26):1982-9. DOI:10.1093/eurheartj/ehs424.

13. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448-53. DOI:10.1038/nm.2307.

14. Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 2012;15(5):606-14. DOI:10.1016/j.cmet.2012.01.024.

15. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009;9(4):311-26. DOI: 10.1016/j.cmet.2009.02.002.

16. Kobalava Z. D., Konradi A. O., Nedogoda S. V., et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786 (In Russ.) https://doi.org/10.15829/15604071-2020-3-3786

17. Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076 (In Russ.) DOI:10.15829/1560-4071-2020-4076.

18. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics. 2006;5(4): 573-88. DOI: 10.1074/mcp.M500331-MCP200.

19. Lee CC, Watkins SM, Lorenzo C, et al. Branched-Chain Amino Acids and Insulin Metabolism: The Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care. 2016;39(4):582-8. DOI:10.2337/dc15-2284.

20. Mahbub MH, Yamaguchi N, Hase R, et al. Plasma Branched-Chain and Aromatic Amino Acids in Relation to Hypertension. Nutrients. 2020;12(12):3791. DOI: 10.3390/nu12123791.

21. Flores-Guerrero JL, Connelly MA, Shalaurova I, et al. A metabolomic index based on lipoprotein subfractions and branched chain amino acids is associated with incident hypertension. Eur J Intern Med. 2021;94:56-63. DOI:10.1016/j.ejim.2021.07.002.

22. Shah SH, Bain JR, Muehlbauer MJ, et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet. 2010;3(2):207-14. DOI:10.1161/CIRCGENETICS.109.852814.

23. Lind L. A detailed lipoprotein profile in relation to intima-media thickness and echogenicity of three major arteries. Clin Physiol Funct Imaging. 2019;39(6):415421. DOI:10.1111/cpf.12594.

24. Mao Z, Zhang W. Role of mTOR in Glucose and Lipid Metabolism. Int J Mol Sci. 2018;19(7):2043. DOI:10.3390/ijms19072043.

25. Eguchi A, Iwasa M, Tamai Y, et al. Branched-chain amino acids protect the liver from cirrhotic injury via suppression of activation of lipopolysaccharide-binding protein, toll-like receptor 4, and signal transducer and activator of transcription 3, as well as Enterococcus faecalis translocation. Nutrition. 2021;86:111194. DOI:10.1016/j.nut.2021.111194.

26. Fang X, Miao R, Wei J, et al. Advances in multi-omics study of biomarkers of glycolipid metabolism disorder. Comput Struct Biotechnol J. 2022;25(20):59355951. DOI: 10.1016/j.csbj.2022.10.030.

27. Després JP, Lamarche B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334(15):952-7. DOI:10.1056/NEJM199604113341504.

28. Lavrenova EA, Drapkina OM. Insulin resistance in obesity: pathogenesis and effects. Obesity and metabolism. 2020;17(1):48-55 (In Russ.) DOI:10.14341/omet9759.